Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias
Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias
复制标题
ADAR1亚型在中国儿童急性白血病中的异常表达。
DOI：
10.1016/j.bbrc.2011.02.025
复制
发表时间：
2011-03-11
影响因子：
3.1
通讯作者：
Zheng, Guo-Guang
中科院分区：
文献类型：
--
作者：
Ma, Cui-Hua;Chong, Jing-Hui;Zheng, Guo-Guang
由1型腺苷脱氨酶作用于RNA（ADAR 1）的转录后RNA编辑，表达为p110和p150亚型，对于生理和病理过程都是重要的。它们在白血病中的表达和意义仍然未知。本研究采用实时荧光定量PCR和Western blot检测ADAR 1在中国儿童急性白血病中的表达。结果表明，p110在白血病中有明显的高表达，尤其是在B-ALL中，而p150的表达略有增加。此外，在达到完全缓解的B-ALL患者中观察到p110表达降低。在ALL的预后危险组中，标准危险组p110和p150表达最高，高危组p110和p150表达最低。基于预后相关临床特征，在预后良好和预后不良组之间的比较中进一步证实了这一观察结果。这些结果表明，ADAR 1亚型表现出不同的表达模式，表明它们可能在儿童白血病中发挥不同的作用。我们的研究结果将有助于我们更好地了解RNA编辑，探索潜在的治疗靶点，并对儿童白血病的预后进行评估。(C)2011 Elsevier Inc. All rights reserved.
The posttranscriptional RNA editing by the type 1 adenosine deaminase acting on RNAs (ADAR1), expressed as p110 and p150 isoforms, is important for both physiological and pathological processes. Their expression and significance in leukemias remain unknown. Here, we investigated the expression of ADAR1 in Chinese pediatric acute leukemias by real-time PCR and Western blot. The results showed that significant high expression of p110 was detected in leukemias, especially in B-ALL, whereas a slight increase of p150 could be observed. Furthermore, the decrease of p110 expression was observed in B-ALL patients achieving complete remission. Moreover, among prognostic risk groups in ALL the highest expressions of p110 and p150 were detected in standard-risk group, whereas their lowest expressions were in high-risk group. This observation was further confirmed in comparisons between good and poor prognostic groups based on prognostic related clinical features. These results demonstrated that ADAR1 isoforms showed different expression patterns, suggesting that they might play different roles in pediatric leukemias. Our results will help us for the better understanding of RNA editing, exploring the potential target for the treatment, and making prognostic evaluation in childhood leukemias. (C) 2011 Elsevier Inc. All rights reserved.